A499 1.25 hospitalizations. Diagnostic tests were also more frequent (rectosigmoidoscopy: 49.3%; abdominal echography: 43.6%) except thyroid function (70.0%). The annual cost of second line was € 2,114 [1,509;2,819] versus € 2,920 [2,072;3,917] after second line failure. Hospitalizations accounted for about 75% of the costs. ConClusions: IBS with constipation leads to significant resource use and high costs certainly in case of second line treatment failure.
objeCtives: Using patient-reported and observer-reported outcome measures to assess symptoms in children is challenging. While the child is arguably the most 'valid' reporter, parents may provide more reliable responses. Our aim was to assess the agreement in child and parent ratings of CC/IBS-C symptoms collected through an electronic daily diary (eDiary). Methods: Separate child and parent eDiaries were developed to assess CC/IBS-C symptoms based on concept elicitation interviews with 64 children and 75 parents. The eDiaries were completed by 36 children (aged 6-11) and 30 parents for 5-9 days prior to cognitive debriefing interviews. eDiary data were compared for five symptoms: abdominal pain, bowel movement (BM) frequency, stool form/consistency, straining and rectal pain during defecation. Results: There were moderate to high levels of agreement (children/ parents selecting the same level of response on a given day) for all items, including 66.9% agreement for BM frequency; 70.2% for stool form and 72.5% for rectal pain. Children's reports of their 'tummy hurting' were consistent with parents seeing their child holding his/her tummy (68.5% agreement) and parents being told by the child that his/her tummy hurt (76.4% agreement). Children's reports of straining were consistent with parents observing their child making a face (60.4% agreement) and hearing their child grunt (52.3% agreement) during defecation. Across all symptoms, agreement was higher for 6-8 year old children and their parents (mean 76.9% agreement) compared to 9-11 year old children and their parents (mean 58.4%). ConClusions: The results present evidence of moderate to strong agreement between children's and parents' reports of core CC/IBS-C symptoms. Lower levels of agreement in ratings amongst 9-11 year old children and their parents may be due to parents being less aware of their child's symptoms.
PGi40
ValiDatinG the uniDimensional fatiGue imPaCt sCale (u-fis) for use in Crohn's Disease objeCtives: Fatigue is usually defined as a feeling of exhaustion, lack of energy or tiredness and affects many aspects of daily living. Crohn's Disease (CD) is often associated with severe fatigue. The Fatigue Impact Scale (FIS) was developed to determine the mental and physical impacts of fatigue. It has been simplified and shortened to 22 items and shown by Rasch analysis to be unidimensional. This version is called the U-FIS. The study was designed to determine the validity of the U-FIS when used with CD patients. Methods: CD patients were asked to complete the U-FIS and a subset of respondents completed it again two weeks later to assess test-retest reliability. Rasch analysis was applied to U-FIS data to determine unidimensionality. Construct validity was further assessed by relating scores on the U-FIS to those on the Crohn's Life Impact Scale (CLIQ) and the Nottingham Health Profile (NHP). Results: A total of 158 CD patients (36.1% female; aged 16-79 years (mean: 42.4; SD 15.0)) completed the U-FIS, with 103 completing it a second time. Overall fit to the Rasch model was confirmed (p = 0.61) and no items misfit. Internal consistency (0.98) and reproducibility (test-retest reliability = 0.88) for the U-FIS were good. U-FIS scores correlated 0.79 with those on the CLIQ indicating the importance of fatigue to quality of life. U-FIS scores were also related as expected with NHP section scores. ConClusions: The U-FIS is a reliable and valid instrument for measuring fatigue in Crohn's Disease. These findings replicate those found with the use of the measure with patients who have Multiple Sclerosis. The U-FIS is valuable as it provides a holistic index of the impact of fatigue from the patient's perspective. The measure may prove valuable for use with patients who have a wide variety of chronic conditions.
PGi41
ValiDation of the Crohn's life imPaCt Questionnaire (CliQ), the first Patient-rePorteD outCome measure sPeCifiC to aDults with Crohn's Disease objeCtives: The study was designed to identify the final CLIQ -the first patientreported outcome measure specific to adults with Crohn's Disease (CD) and determine its unidimensionality, reproducibility and construct validity. The measure has two scales; Activity limitations and needs-based Quality of Life (QoL). Methods: CD patients were sent a package consisting of the CLIQ, the Nottingham Health Profile (NHP), the Unidimensional Fatigue Impact Scale (U-FIS) and a demographic questionnaire. A subset of respondents received a second questionnaire package 2 weeks later. Rasch analysis was applied to responses for item reduction and assessment of unidimensionality. Assessments of internal consistency, test-retest reliability and construct validity were also undertaken. Results: The CLIQ was completed by 273 CD patients (65.6% female; aged 16-79 years (mean: 43.9; SD 15.1).
PGi36 the Cost effeCtiVeness of PeGinterferon alfa anD riBaVirin for the treatment of hePatitis C in ChilDren anD younG PeoPle
Cooper K. 1 , Baxter L. 2 , Loveman E. 1 , Hartwell D. 1 , Frampton G. 1 1 University of Southampton, Southampton, UK, 2 London School of Hygiene, London, UK objeCtives: To assess the cost-effectiveness of peginterferon α -2a and peginterferon α -2b in combination with ribavirin compared to best supportive care (BSC), for the treatment of chronic hepatitis C virus (HCV) in children and young people aged 3 to 17 years. Methods: A Markov state-transition economic model of chronic HCV in children and young people was developed that extrapolated the impact of sustained virological response (SVR) on life expectancy, quality-adjusted life expectancy and lifetime costs. The model was adapted from one previously developed for adults. A systematic review was conducted of the clinical effectiveness of the treatments, and the health related quality of life for patients with hepatitis C. Uncertainty was explored through probabilistic and deterministic sensitivity analyses. Results: Seven studies were identified that were relatively small and of generally poor quality. Estimates of SVR were similar for peginterferon α -2a (60%) and peginterferon α -2b (58%), whilst the SVR for no treatment was assumed to be zero. From this model, peginterferon alfa (α -2a or α -2b) in combination with ribavirin was more effective and cheaper than BSC. Sensitivity analyses suggest that the results were generally robust to all changes to the structural assumptions and input parameters. The model results were most sensitive to changes to the discount rate, time horizon, SVR and baseline fibrosis of the cohort. ConClusions: Treatment of children and young people with peginterferon alfa (α -2a or α -2b) and ribavirin may be an effective therapy. Peginterferon alfa (α -2a or α -2b) in combination with ribavirin is cost-effective compared with BSC. However, the available evidence is of poor quality. The views expressed in this paper are those of the authors and do not necessarily represent the views or policies of the UK HTA programme or Department of Health.
PGi37

Cost-utility analysis of telaPreVir in ComBination with PeGinterferon alPha anD riBaVirin in PreViously untreateD Patients with ChroniC hePatitis in a romanian settinG
Paveliu M. S. 1 , Comsa R. 2 , Mircea R. 2 1 Titu Maiorescu University, Bucharest, Romania, 2 Mind Research&Rating s.r.l., Bucharest, Romania objeCtives: To estimate the cost-effectiveness in Romanian setting of triple therapy with Telaprevir and Peginterferon/Ribavirin (TVR+PR) compared with PR alone in previously untreated patients with hepatitis C virus (HCV) infection from the third payer -National Health Insurance Agency (NHIA). Methods: We used the published data of efficacy from large international trials and published Markov models to estimate the cost-effectiveness of this new HCV serine protease inhibitor (telaprevir) using the specific local cost and epidemiological data. The superior results shown by Jacobson IM et all in ADVANCE trial -(Telaprevir for previously untreated chronic hepatitis C virus infection) for telaprevir -75% sustained virologic response compared with 44% for PR alone. The discount rate was 3% for both cost and efficacy. Cost were extracted from NIHA tarrifs, Minister of Health drugs price catalog and from previous published data. The reference patient was a 45-year-old male with chronic liver disease due to chronic HCV infection. Time horizon was set patient life time. The clinical outcomes and Utilities for all health states were taken from ADVANCE phase-3 trial. The comparator was Peginterferon 2alfa with ribavirin. The effectiveness was measured in quality-adjusted life years (QALY).The cost of secondary drug reactions were not included in the model. Results: Incremental cost effectiveness ratio (ICER) for telaprevir in combination with PR compared to PR alone was 23291 € /1 gained QALY. ConClusions: As in Romania HTA is only at the beginning, health authorities has to evaluate the most cost-effective strategy to follow for treatment of patients with chronic hepatitis as ICER of telaprevir in combination with PR compared with PR alone is reaching or is above the level recommended by Word Health Organisation as upper threshold (3 GDP/capita -Romania's GDP/ capita is 6200Euro). Further CUA should be performed, including for guided therapy and treatment designated to previous treated patients.
PGi38 the Current manaGement anD Costs of irritaBle Bowel synDrome with ConstiPation in BelGium: a 2-rounD exPert surVey
Caekelbergh K. 1 , Gerlier L. 1 , Lamotte M. 1 , Kinoo D. 2 , Meurgey F. 3 , Berdeaux G. 1 1 IMS Health HEOR, Vilvoorde, Belgium, 2 Almirall, Vilvoorde, Belgium, 3 Oukelos sprl, Brussels, Belgium objeCtives: Patients suffering from irritable bowel syndrome (IBS) with constipation (IBS-C) receive laxatives as first line therapy. In spite of these laxatives most of them experience failure. We aimed at describing the current management and its costs of Belgian IBS-C patients who failed first line treatment. Methods: A 2-round Delphi panel was conducted including general practitioners (GP) and gastroenterologists. The type and frequency of medical resources used per year as second-line IBS-C therapy (consultations, exams/tests, drugs, hospitalizations) were collected, reflecting the expert's own practice in the first round and finding a Belgian consensus in the second round. Two patients' profiles were defined: second line current management and third line management in case of second line failure. Unit costs (2012 INAMI/RIZIV tariffs) were assigned to the resources used to calculate a cost per patient-year and a range based on the distribution of experts' answers. Results: Eleven experts participated (6 GPs/5 gastroenterologists). The drugs prescribed in second line were laxatives (71.4%, mainly osmotics), spasmolytics (72.2%), pain killers (11.5%) and antidepressants (6.0%). There were 7.7 consultations per patient-year on average (GP: 5.3; specialists: 2.4). Emergency room visits occurred in 10.4% and diagnostic tests included thyroid function (79.1%), rectosigmoidoscopy (39.8%) and abdominal echography (36.8%). There were 0.97 IBSrelated admissions to hospital per patient-year. After a second line failure, resource use increased with more laxatives (75.5%), antidepressants (24.6%) and pain killers (17.3%), 11.6 consultations (GP: 7.5; specialist: 4.1), 14.5% emergency room visits and
